Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

被引：0

作者：

Kersten, Marie Jose ^{[1
,2
]}

Dreyling, Martin ^{[3
]}

Linton, Kim M. ^{[4
,5
]}

Chitu, Dana ^{[6
]}

Tonino, Sanne ^{[7
]}

Kap, Marcel ^{[8
]}

Liu, Roberto D. ^{[9
]}

Chamuleau, Martine E. D. ^{[10
]}

Visser, Hein P. J. ^{[11
]}

De Jongh, Eva ^{[12
]}

Marijt, Erik Waf ^{[13
]}

Leijs, Maria B. L. ^{[14
,15
]}

Bilgin, Yavuz M. ^{[16
]}

Duerig, Jan ^{[17
]}

McKay, Pamela ^{[18
]}

Snijders, Tjeerd J. F. ^{[19
]}

Pettitt, Andrew ^{[20
,21
]}

Minnema, Monique C. ^{[22
]}

Prange-Krex, Gabriele ^{[23
]}

Cuijpers, Maria ^{[24
]}

Boehmer, Lara H. ^{[25
]}

Tick, Lidwine W. ^{[26
]}

Florschuetz, Axel ^{[27
]}

Silbermann, Matthijs ^{[28
]}

Fijnheer, Rob ^{[29
]}

Beeker, Aart ^{[30
]}

Tolboom, Nelleke ^{[31
]}

Mitea, Cristina ^{[32
]}

Arens, Anne I. J. ^{[33
]}

Zwezerijnen, Gerben J. C. ^{[34
]}

Klapper, Wolfram ^{[35
]}

Coupland, Sarah E. ^{[36
]}

de Jong, Daphne ^{[37
]}

Doorduijn, Jeanette K. ^{[38
]}

Zijlstra, Josee M. ^{[10
]}

机构：

[1] Amsterdam Univ Med Ctr, Locat Univ Amsterdam, Amsterdam, Netherlands

[2] Canc Ctr Amsterdam, Amsterdam, Netherlands

[3] Klinikum Univ Muenchen, Dept Med 3, Campus Grosshadern, Munich, Germany

[4] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[5] Christie Hosp, Manchester, Lancs, England

[6] Erasmus MC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[7] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands

[8] ErasmusMC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[9] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[10] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[11] Med Ctr Alkmaar, Hematol, Alkmaar, Netherlands

[12] Albert Schweitzer Hosp, Dept Hematol, Dordrecht, Netherlands

[13] Leiden Univ Hosp, Hematol, Leiden, Netherlands

[14] Maasstad Ziekenhuis, Rotterdam, Netherlands

[15] Maasstad Ziekenhuiis, Rotterdam, Netherlands

[16] Admiraal de Ruijter Hosp, Dept Internal Med, Goes, Netherlands

[17] Essen Univ Hosp, Dept Hematol, Essen, Germany

[18] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[19] Med Spectrum Twente, Enschede, Netherlands

[20] Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, Merseyside, England

[21] Univ Liverpool, Liverpool, Merseyside, England

[22] Univ Med Ctr, Dept Hematol, Utrecht, Netherlands

[23] Gemeinschaftspraxis Mohm Prange Krex, Dresden, Germany

[24] Viecuri Med Ctr, Venlo, Netherlands

[25] Haga Teaching Hosp, Dept Hematol, The Hague, Netherlands

[26] Maxima Med Ctr, Veldhoven, Netherlands

[27] Klinikum Dessau, Hematol, Dessau, Germany

[28] Ter Gooi Hosp, Hilversum, Netherlands

[29] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands

[30] Sparne Ziekenhuis, Hoofddorp, Netherlands

[31] Univ Med Ctr Utrecht, Nucl Med, Utrecht, Netherlands

[32] Maastricht Univ, Med Ctr, Nucl Med, Maastricht, Netherlands

[33] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[34] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC,Locat VUmc, Amsterdam, Netherlands

[35] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

[36] Univ Liverpool, Pathol, Liverpool, Merseyside, England

[37] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands

[38] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-156085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2283 / 2285

页数：3

共 50 条

[41] CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
Martin, Peter
Jung, Sin-Ho
Johnson, Jeffrey L.
Pitcher, Brandy
Elstrom, Rebecca L.
Bartlett, Nancy
Blum, Kristie A.
Richards, Kristy L.
Leonard, John
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
Batlevi, Connie Lee
Salles, Gilles
Park, Steven, I
Phillips, Tycel J.
Amengual, Jennifer E.
Andorsky, David
Campbell, Philip
McKay, Pamela
Leonard, John P.
Sondhi, Manu
Chen, Yingxue
Slatcher, Pamela L.
Lin, Richard
Szanto, Attila
Abbadi, Sara
Morschhauser, Franck
BLOOD, 2022, 140 : 2296 - 2298
[43] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
Ahmadi, Tahamtan
Chong, Elise A.
Gordon, Amanda
Leinbach, Leah
Aqui, Nicole A.
Nasta, Sunita D.
Svoboda, Jakub
Goldstein, Steven C.
Schuster, Stephen J.
BLOOD, 2010, 116 (21) : 1616 - 1616
[44] Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Franck Morschhauser
Nilanjan Ghosh
Izidore S. Lossos
M. Lia Palomba
Amitkumar Mehta
Olivier Casasnovas
Don Stevens
Sudhakar Katakam
Andrea Knapp
Tina Nielsen
Ron McCord
Gilles Salles
Blood Cancer Journal, 11
[45] Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Morschhauser, Franck
Ghosh, Nilanjan
Lossos, Izidore S.
Palomba, M. Lia
Mehta, Amitkumar
Casasnovas, Olivier
Stevens, Don
Katakam, Sudhakar
Knapp, Andrea
Nielsen, Tina
McCord, Ron
Salles, Gilles
BLOOD CANCER JOURNAL, 2021, 11 (08)
[46] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P.
Trneny, Marek
Izutsu, Koji
Fowler, Nathan H.
Hong, Xiaonan
Zhu, Jun
Zhang, Huilai
Offner, Fritz
Scheliga, Adriana
Nowakowski, Grzegorz S.
Pinto, Antonio
Re, Francesca
Fogliatto, Laura Maria
Scheinberg, Phillip
Flinn, Ian W.
Moreira, Claudia
Cabecadas, Jose
Liu, David
Kalambakas, Stacey
Fustier, Pierre
Wu, Chengqing
Gribben, John G.
Calaminici, Maria
Copie-Bergman, Christiane
Lopez-Guillermo, Armando
O'Connor, Owen
Williams, Michael
Suciu, Stefan
Levine, Benjamin
Kern, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
[47] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Coleman, Morton
Kolibaba, Kathryn S.
Brooks, Heather Dawn
Bitran, Jacob D.
Fanning, Suzanne R.
Lansigan, Frederick
Ricker, Justin L.
Foon, Kenneth A.
Liu, Dongfang
Llorente, Mary
Li, Jiahui
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[48] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Badoux, Xavier C.
Keating, Michael J.
Wen, Sijin
Wierda, William G.
O'Brien, Susan M.
Faderl, Stefan
Sargent, Rachel
Burger, Jan A.
Ferrajoli, Alessandra
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591
[49] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Vitolo, Umberto
Merli, Michele
Norasetthada, Lalita
Wassenaar, Timothy Robert
Martin, Eva Maria Donato
Bobillo, Sabela
Shen, Biyi
Flink, Dina M.
Zhu, Min
Chandrasekharan, Soujanya
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Cordoba, Raul
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
Zinzani, Pier Luigi
Pellegrini, Cinzia
Gandolfi, Letizia
Stefoni, Vittorio
Quirini, Federica
Derenzini, Enrico
Broccoli, Alessandro
Argnani, Lisa
Pileri, Stefano
Baccarani, Michele
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466

← 1 2 3 4 5 →